Iloprost Zentiva

Iloprost, the active ingredient in Iloprost Zentiva, is a prostacyclin analog presented as an inhalation solution for nebulization use. It treats pulmonary arterial hypertension in adult patients by improving vascular tone and exercise capacity.

GNH USA supplies Iloprost Zentiva as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Iloprost acts on the prostacyclin pathway to manage pulmonary vascular disease.

Pulmonary arterial hypertension: improves exercise capacity and delays disease progression. Chronic thromboembolic pulmonary hypertension: used as adjunct therapy to improve hemodynamics. Digital ulcers in systemic sclerosis: may promote ulcer healing and reduce pain.

Common Side Effects: - Cough or throat irritation during inhalation - Headache - Flushing or warmth sensation - Nausea or dyspepsia

Serious or Rare Side Effects: - Significant hypotension or syncope - Pulmonary edema - Severe bronchospasm or respiratory distress - Bleeding complications, including hemoptysis

Patients receiving Iloprost should be monitored closely for cardiovascular and respiratory safety.

Monitor blood pressure: watch for hypotension after inhalation. Assess bleeding risk: avoid in patients with active hemorrhage or on strong anticoagulants. Evaluate liver function: adjust use if hepatic impairment is present. Avoid use in recent myocardial infarction: defer therapy for at least 30 days post‑event. Store at room temperature: keep in original container, protect from moisture and light.

Iloprost may interact with other agents that affect vascular tone or platelet function.

Major Interactions (Avoid): - Concurrent use of potent vasodilators (e.g., nitroglycerin) may cause severe hypotension. - Strong anticoagulants (e.g., warfarin) increase risk of bleeding. - Phosphodiesterase‑5 inhibitors combined with high‑dose Iloprost may amplify vasodilatory effects.

Moderate Interactions (Monitor Closely): - Aspirin or other antiplatelet drugs: monitor for bleeding. - Other pulmonary arterial hypertension therapies (e.g., endothelin receptor antagonists): adjust dosing as needed. - Smoking or nicotine products: may reduce drug efficacy.